Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.64 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.64 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TXN | P10599 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL1286383 | 0.98 | EHMT2 (0.61) | EHMT2EHMT1APOBEC3GLMNAFBP1 | |
| SCHEMBL30195130 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GLMNAALDH1A1 | |
| SCHEMBL423720 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GLMNAALDH1A1 | |
| Acrylic Acid SCHEMBL29224774 | 0.84 | EHMT2 (0.46) | EHMT2EHMT1APOBEC3GLMNAALDH1A1 | |
| Methacrylic Acid SCHEMBL28950373 | 0.84 | EHMT2 (0.46) | EHMT2EHMT1APOBEC3GLMNAALDH1A1 | |
| Acrylamide SCHEMBL23804873 | 0.83 | EHMT2 (0.44) | EHMT2EHMT1APOBEC3GLMNAALDH1A1 | |
| SCHEMBL14157325 | 0.83 | EHMT2 (0.44) | EHMT2EHMT1APOBEC3GLMNAALDH1A1 | |
| SCHEMBL2618715 | 0.83 | EHMT2 (0.77) | EHMT2EHMT1APOBEC3GLMNAALDH1A1 | |
| SCHEMBL11833495 | 0.83 | EHMT2 (0.70) | EHMT2EHMT1APOBEC3GLMNAALDH1A1 | |
| SCHEMBL12107793 | 0.81 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118330218-A | Cathepsin B targeted activation type PET molecular probe and application thereof | 江苏省原子医学研究所 | 2024-07-12 | — | — | CN | claimed |
| CN-113388003-B | Aspartic acid proteolytic enzyme recognition reduction type molecular probe and application | 江苏省原子医学研究所 | 2023-04-07 | — | — | CN | claimed |
| CN-113388003-A | Aspartic acid proteolytic enzyme recognition reduction type molecular probe and application | 江苏省原子医学研究所 | 2021-09-14 | — | — | CN | claimed |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | SINGULAR GENOMICS SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250339415-A1 | DISULFIDE COMPOUNDS AS MEDICAMENTS | CYTACOAT AB (SE) | 2025-11-06 | — | — | US | disclosed |
| EP-4380567-B1 | DISULFIDE COMPOUNDS AS MEDICAMENTS | CYTACOAT AB (SE) | 2025-05-07 | — | — | EP | disclosed |
| US-12215122-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-12-05 | — | — | US | disclosed |
| US-12145960-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240316036-A1 | DISULFIDE CONTAINING THERAPEUTICS AND DIAGNOSTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-09-26 | — | — | US | disclosed |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-08-15 | — | — | US | disclosed |
| US-20070087047-A1 | Enhanced circulation effector composition and method | ALZA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-6251858-B1 | DERIVATIVES OF GLYCOSYLAMINE IN WHICH THE OLIGOSIDES ARE FIXED ON AT LEAST ONE MOLECULE, MATRIX OR PARTICLE | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 2001-06-26 | — | — | US | disclosed |
| EP-0766689-A1 | NOVEL OLIGOSACCHARIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USES THEREOF | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 1997-04-09 | — | — | EP | disclosed |
| WO-1996000229-A1 | NOVEL OLIGOSACCHARIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USES THEREOF | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 1996-01-04 | — | — | WO | disclosed |
| US-4237290-A | ODORANTS, FLAVORINGS; REACTION OF A SULFONIUM SALT AND A MERCAPTAN | GIVAUDAN CORPORATION (US) | 1980-12-02 | — | — | US | disclosed |
| US-4188488-A | ALKYLIMIDAZOLYL SUBSTITUENTS | GIVAUDAN CORPORATION (US) | 1980-02-12 | — | — | US | disclosed |
| US-4170594-A | Oxazolyl-alkyl-disulphides as flavorants | GIVAUDAN CORPORATION (US) | 1979-10-09 | — | — | US | disclosed |
| US-4130562-A | Odorant or flavoring thiazolyl disulphides | GIVAUDAN CORPORATION (US) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215122-B2 | Nucleotide analogues | NUDT1, POLN, TYMP | EHMT2 2494/4885EHMT1 2450/4885APOBEC3G 226/4885 |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | EHMT2 938/4885EHMT1 923/4885APOBEC3G 236/4885 |
| US-20250339415-A1 | DISULFIDE COMPOUNDS AS MEDICAMENTS | SQOR, SFXN1, PDIA5 | EHMT2 4300/4885EHMT1 3602/4885APOBEC3G 4248/4885 |
| US-20240316036-A1 | DISULFIDE CONTAINING THERAPEUTICS AND DIAGNOSTICS | GPX1, GPX4, PDIA4 | EHMT2 2946/4885EHMT1 3031/4885APOBEC3G 4047/4885 |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | EHMT2 938/4885EHMT1 923/4885APOBEC3G 236/4885 |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | P4HB, PDIA5, PDIA4 | EHMT2 3151/4885EHMT1 3191/4885APOBEC3G 2768/4885 |
| US-12145960-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.